Viking Therapeutics commences Phase I trial of VK3019

Viking Therapeutics has commenced a Phase I clinical trial of VK3019, a DACRA, which is under development as a potential weight loss treatment option. Primary objectives involve assessing the tolerability, pharmacokinetics and safety of VK3019. Exploratory assessments will track pharmacodynamic changes including body weight after the administration of a single dose. Credit: New Africa/Shutterstock.com. Viking Therapeutics has commenced a Phase I clinical trial of VK3019, a dual amylin and calcitonin receptor agonist, which is under development as a potential weight loss treatment option. The trial follows the US Food and Drug Administration’s acceptance of the investigational new drug application. LOA…

Source: Clinical Trials Arena